☰

Jeremy L. Baryza, Ph.D. - Publications

Affiliations: 
2005 Stanford University, Palo Alto, CA 
Area:
Organic, Organometallic, Bioorganic, and Medicinal Chemistry
Tree Info Similar researchers PubMed Report error

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2011 Wender PA, Baryza JL, Brenner SE, DeChristopher BA, Loy BA, Schrier AJ, Verma VA. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proceedings of the National Academy of Sciences of the United States of America. 108: 6721-6. PMID 21415363 DOI: 10.1073/Pnas.1015270108  0.742
2009 Shaha SP, Tomic J, Shi Y, Pham T, Mero P, White D, He L, Baryza JL, Wender PA, Booth JW, Spaner DE. Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells. Clinical and Experimental Immunology. 158: 186-98. PMID 19737143 DOI: 10.1111/J.1365-2249.2009.04003.X  0.508
2006 Wender PA, Baryza JL, Hilinski MK, Horan JC, Kan C, Verma VA. Beyond Natural Products: Synthetic Analogues of Bryostatin 1 Drug Discovery Research: New Frontiers in the Post-Genomic Era. 125-162. DOI: 10.1002/9780470131862.ch6  0.713
2005 Statsuk AV, Bai R, Baryza JL, Verma VA, Hamel E, Wender PA, Kozmin SA. Actin is the primary cellular receptor of bistramide A. Nature Chemical Biology. 1: 383-8. PMID 16372404 DOI: 10.1038/Nchembio748  0.534
2005 Wender PA, Baryza JL. Identification of a tunable site in bryostatin analogs: C20 Bryologs through late stage diversification. Organic Letters. 7: 1177-80. PMID 15760168 DOI: 10.1021/Ol0501931  0.495
2005 Hammond C, Shi Y, Mena J, Tomic J, Cervi D, He L, Millar AE, Debenedette M, Schuh AC, Baryza JL, Wender PA, Radvanyi L, Spaner DE. Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 28-39. PMID 15614042 DOI: 10.1097/00002371-200501000-00004  0.488
2004 Wender PA, Baryza JL, Brenner SE, Clarke MO, Craske ML, Horan JC, Meyer T. Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. Current Drug Discovery Technologies. 1: 1-11. PMID 16472215 DOI: 10.2174/1570163043484888  0.763
2004 Stone JC, Stang SL, Zheng Y, Dower NA, Brenner SE, Baryza JL, Wender PA. Synthetic bryostatin analogues activate the RasGRP1 signaling pathway. Journal of Medicinal Chemistry. 47: 6638-44. PMID 15588099 DOI: 10.1021/Jm0495069  0.669
2004 Baryza JL, Brenner SE, Craske ML, Meyer T, Wender PA. Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP. Chemistry & Biology. 11: 1261-7. PMID 15380186 DOI: 10.1016/J.Chembiol.2004.06.014  0.703
2003 Wender PA, Baryza JL, Brenner SE, Clarke MO, Gamber GG, Horan JC, Jessop TC, Kan C, Pattabiraman K, Williams TJ. Inspirations from nature. New reactions, new therapeutic leads, and new drug delivery systems Pure and Applied Chemistry. 75: 143-155. DOI: 10.1351/Pac200375020143  0.675
2003 Wender PA, Baryza JL, Brenner SE, Clarke MO, Gamber GG, Horan JC, Jessop TC, Kan C, Pattabiraman K, Williams TJ. Inspirations from nature. New reactions, therapeutic leads, and drug delivery systems Pure and Applied Chemistry. 75: 143-155.  0.628
2002 Wender PA, Baryza JL, Bennett CE, Bi FC, Brenner SE, Clarke MO, Horan JC, Kan C, Lacôte E, Lippa B, Nell PG, Turner TM. The practical synthesis of a novel and highly potent analogue of bryostatin. Journal of the American Chemical Society. 124: 13648-9. PMID 12431074 DOI: 10.1021/Ja027509+  0.683
Show low-probability matches.